Business Wire

BOEHRINGER-INGELHEIM

5.10.2022 09:11:35 CEST | Business Wire | Press release

Share
Last-mile veterinary delivery social start-up Cowtribe first investment of Boehringer Ingelheim Social Engagements

Boehringer Ingelheim announced today that Cowtribe is the first recipient of investment and non-financial support from the Boehringer Ingelheim Social Engagement (BI SE) initiative, a program which aims to close a critical financing gap for social businesses in vulnerable communities.

Cowtribe, a leading last-mile veterinary delivery company from Ghana, leverages technology to help coordinate deliveries of veterinary vaccines and other animal health products to rural and underserved communities, where many farmers are dependent on just a few animals.

With innovative solutions, such as software supported demand & supply matching, as well as a partnership for drone delivery, Cowtribe bridges the final, critical last mile to get animal medication and veterinary vaccines to smallholder farmers in remote areas. The social start-up, which was founded in 2017, plans to expand to other African markets and collaborates with the government of Ghana on a national livestock identification system, based on Cowtribe’s market data and network.

Start-ups often need more than just funding. BI SE was launched in 2021 to provide investment and non-financial support, together with complementary partners and by engaging Boehringer Ingelheim’s employees to help scale up solutions of social businesses to create systemic change.

BI SE underlines Boehringer Ingelheim’s commitment to find innovative financing solutions with the intention to scale social impact. It complements Boehringer Ingelheim’s flagship initiative, Making More Health, which has committed to positively impact the lives and health of 50 million people through supporting social entrepreneurs in vulnerable communities.

“We are delighted to grant the first investment of Boehringer Ingelheim Social Engagements to Cowtribe,” said Ilka Wicke, Global Head of Making More Health at Boehringer Ingelheim. “Every year smallholder farmers lose about 25 percent of their livestock, due to preventable diseases. Cowtribe is at the forefront of addressing this problem by transforming the critical last-mile distribution in Africa. Their smart logistics platform, based on demand optimization, combined with innovative drone delivery concepts, helps secure the availability and accessibility of vaccines for smallholder farmers. Together, we can significantly improve the lives of many farmers across Africa.”

“In Africa, there are over 200 million smallholder farmers without access to reliable animal health services. We are incredibly excited to partner with BI SE to support our mission to make access to animal vaccines in Africa a right, not a privilege,” added Peter Awin, co-founder and CEO of Cowtribe. “This funding will be used to accelerate our growth in Ghana. This will involve entering new communities and building robust tech capabilities, product development, and attracting new talent.”

Financial details will not be disclosed. The news was announced during the “Making More Health Together 2022" convention, a two-day hybrid event, which focuses on the empowerment of social entrepreneurship and topics relevant to human and animal health, as well as social innovation.

Click here for the full release: https://www.boehringer-ingelheim.com/investment-social-engagements-cowtribe-veterinary-startup

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

View source version on businesswire.com: https://www.businesswire.com/news/home/20221005005338/en/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com
DK

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

From London 1851 to Riyadh 2030: The United Kingdom Continues Its World Expo Legacy with the Signing of Its Participation Contract for Expo 2030 Riyadh19.11.2026 15:10:00 CET | Press release

The United Kingdom has signed its Participation Contract for Expo 2030 Riyadh, confirming its place at one of the world’s largest global gatherings. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119617914/en/ The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State for Foreign Affairs, Climate Envoy, and Commissioner General of Expo 2030 Riyadh; and Lord Sarwar, UK Minister for Trade; and Talal Al-Marri, CEO of Expo 2030 Riyadh. The Agreement constitutes a significant milestone in the United Kingdom’s journey towards Expo 2030 Riyadh, establishing the framework for the execution of its pavilion, programming and visitor experience. This latest agreement adds to a growing number of Participation Contract signings, reflecting increasing momentum behind Expo 2030 Riyadh and the value countries are placing on being part of it. The Participation Contract was signed by H.E Adel Al-Jubeir, Minister of State

Rimini Street to Host Investor Day on January 14, 2027, in New York City19.11.2026 15:00:00 CET | Press release

The Company will highlight its opportunities and unique solutions in enterprise software support and its ownership of the Agentic AI ERP market, present its sales strategy and financial model and host a panel discussion featuring Rimini Street global clients from a variety of industries Rimini Street, Inc. (Nasdaq: RMNI), a global provider of end-to-end enterprise software support, managed services and Agentic AI ERP innovation solutions, and the leading third-party support provider for Oracle, SAP and VMware software, today announced details for its upcoming Investor Day, to be held on January 14, 2027, in New York City. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119878624/en/ Rimini Street to Host Investor Day on January 14, 2027, in New York City Investor Day Details Date: January 14, 2027 Time: 8:30 a.m. – 12:30 p.m. Eastern Time Location: New York City In-Person Attendance: Institutional investors and analysts in

Belkin Named CES Innovation Awards® 2027 Honoree for Titan SmartShield Pro Bright Privacy Screen Protector19.11.2026 15:00:00 CET | Press release

Award-winning screen protection technology redefines mobile privacy with a brighter, clearer viewing experience and improved power efficiency Belkin, a leading consumer electronics brand for over 40 years, today announced that its Titan SmartShield Pro Bright Privacy Screen Protector has been named a CES Innovation Awards® 2027 Honoree in the Mobile Devices, Accessories & Apps category. The recognition celebrates Belkin's innovative approach to screen protection, combining enhanced privacy, optical clarity and durability without compromising the everyday smartphone experience. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20261119118768/en/ Belkin Named CES Innovation Awards® 2027 Honoree for Titan SmartShield Pro Bright Privacy Screen Protector The CES Innovation Awards® 2027 program received a record number of submissions – nearly 4,000 – ahead of CES 2027, taking place January 6–9 in Las Vegas. The annual competition, owne

Marsh’s Oliver Wyman to Acquire Financial Services and Technology Consultancy Synpulse19.11.2026 14:08:00 CET | Press release

Oliver Wyman, a global leader in management consulting and a Marsh business (NYSE:MRSH), today announced an agreement to acquire Synpulse, a global technology consulting and AI platform company serving banks, insurers, wealth managers and other financial services organizations. Terms of the deal, expected to close in early 2027, were not disclosed. Banks, insurers and asset managers face significant changes driven by advances in technology, data and AI, as well as evolving business models. As these changes accelerate, clients are looking for partners who can help them navigate every stage of transformation, from strategy to technology implementation and execution. Oliver Wyman and Synpulse have already been working together with combined teams on multiple end-to-end transformations for our clients. The acquisition will enable the two businesses to continue to work closely together, combining complementary capabilities and teams to service clients across strategy, technology and impleme

GE HealthCare’s Phase 2 Results Support Advancement of Investigational Manganese-Based MRI Contrast Agent Mangaciclanol Into Phase 3 of LUMINA Clinical Trial19.11.2026 14:00:00 CET | Press release

Key milestone in GE HealthCare’s adaptive Phase 2/3 LUMINA clinical trial, with Phase 2 results meeting primary endpoint, showing mangaciclanol and market-leading gadolinium-based agent, gadobutrol, have similar overall diagnostic preference Mangaciclanol was well tolerated in the Phase 2 stage, with no safety concerns identified following its administration Mangaciclanol has received FDA Fast Track designation, recognizing its potential to address significant unmet patient needs; approximately 65 million gadolinium-enhanced MRI procedures are performed each year GE HealthCare to present preliminary Phase 2 results at RSNA 2026 (Industry Expert Theater) GE HealthCare (Nasdaq: GEHC) today announced Phase 2 results support advancement into Phase 3 for its international, multicenter LUMINA trial of mangaciclanol, with a dose selection of 0.1mmol/kg. Mangaciclanol is an investigational manganese-based magnetic resonance imaging (MRI) contrast agent (MBCA). If approved, MBCAs could offer an

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye